NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019
Identifying individuals with hereditary syndromes allows for improved cancer surveillance, risk reduction, and optimized management. Establishing criteria for assessment allows for the identification of individuals who are carriers of pathogenic genetic variants.
Category
  • Colorectal Cancer
Format
  • Monograph/Journal Supplement
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Colorectal Cancer
Personalizing treatment selection for each patient with localized colon cancer or metastatic colorectal cancer (mCRC) can maximize the benefits while minimizing the harms to give each patient the best survival and quality of life possible. Clinicians must be knowledgeable about new trial results, new systemic therapy options, new biomarkers, and other treatment-selection criteria in order to help patients make the best informed decisions possible.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers
There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.
Category
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers
There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.
Category
  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation